Soc (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 47 | バージャー病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02501018 (ClinicalTrials.gov) | November 1, 2017 | 14/7/2015 | Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) | A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD) | Critical Limb Ischemia;Buerger Disease;Thromboangiitis Obliterans;Atherosclerosis Obliterans | Biological: CLBS12;Drug: SOC | Caladrius Biosciences, Inc. | NULL | Recruiting | 20 Years | 85 Years | All | 35 | Phase 2 | Japan |